BioMarin’s VOXZOGO Shows Long-Term Bone Health and Growth Benefits in Children With Achondroplasia
- Presented new data at the Pediatric Endocrine Society's 2026 Annual Meeting regarding the long-term effects of VOXZOGO (vosoritide) in children with achondroplasia.
- According to reporting from Stock Titan, a six-year study associated with the treatment found that bone health was maintained in children administered VOXZOGO.
- The presentation delivered by BioMarin highlighted specific metrics related to the physical progression of children with achondroplasia, a form of short-limb dwarfism.
BioMarin Pharmaceutical Inc. Presented new data at the Pediatric Endocrine Society’s 2026 Annual Meeting regarding the long-term effects of VOXZOGO (vosoritide) in children with achondroplasia. The findings focused on the impact of extended treatment on bone health, arm span, and overall growth.
According to reporting from Stock Titan, a six-year study associated with the treatment found that bone health was maintained in children administered VOXZOGO. The data presented at the meeting detailed how the long-term application of the drug influenced physical development in patients with the genetic condition.
Clinical Focus and Patient Outcomes
The presentation delivered by BioMarin highlighted specific metrics related to the physical progression of children with achondroplasia, a form of short-limb dwarfism. The data set specifically examined changes in arm span and bone health, alongside general growth trajectories over a multi-year period.
VOXZOGO is designed to target the underlying cause of achondroplasia by mimicking the action of C-type natriuretic peptide (CNP). By doing so, the medication aims to reduce the overactivity of fibroblast growth factor receptor 3 (FGFR3), which typically inhibits bone growth in affected individuals.
The six-year duration of the study provides a longitudinal view of the drug’s efficacy, addressing critical questions regarding whether the growth-promoting effects of vosoritide are sustainable and whether the treatment impacts the structural integrity of the skeletal system over time.
Business and Market Implications
From a corporate perspective, the presentation of long-term safety and efficacy data is a significant milestone for BioMarin. For chronic pediatric therapies, demonstrating that a drug maintains its benefit over several years without compromising bone health is essential for maintaining market share and supporting long-term prescription rates.
The ability to provide data spanning six years allows the company to offer clinicians more certainty regarding the long-term trajectory of patients on the therapy. This represents particularly relevant in the competitive landscape of rare disease treatments, where long-term outcome data often influences payer reimbursement decisions and clinical guidelines.
Achondroplasia represents a significant unmet medical need, and VOXZOGO has positioned BioMarin as a primary provider of pharmacological intervention for the condition. The continued verification of bone health maintenance suggests a favorable safety profile for the medication as children progress through different stages of skeletal development.
The data presented at the Pediatric Endocrine Society’s 2026 Annual Meeting reinforces the clinical utility of vosoritide in managing the physical manifestations of achondroplasia. By documenting the effects on arm span and growth, BioMarin provides a benchmark for the expected physical outcomes of long-term adherence to the treatment regimen.